Faculty
Kelvin C Luk, PhD MTR
Associate Professor of Pathology and Laboratory Medicine
Department: Pathology and Laboratory Medicine
Graduate Group Affiliations
Contact information
3600 Spruce St
1 Maloney Building
HUP
Philadelphia, PA 19104
1 Maloney Building
HUP
Philadelphia, PA 19104
Office: 215-615-3202
Fax: 215-615-3206
Lab: 215-662-3292
Fax: 215-615-3206
Lab: 215-662-3292
Publications
Education:
BSc (Microbiology and Immunology)
McGill University, 1997.
PhD (Pathology)
McGill University, 2004.
MSTR (Translational Research)
University of Pennsylvania, 2013.
Permanent linkBSc (Microbiology and Immunology)
McGill University, 1997.
PhD (Pathology)
McGill University, 2004.
MSTR (Translational Research)
University of Pennsylvania, 2013.
Description of Research Expertise
My research aims to improve our understanding of the synucleinopathies, a group of neurodegenerative disorders that include Parkinson’s disease (PD), Lewy body dementia and multiple system atrophy (MSA). PD is a progressive neurodegenerative condition that affects over 1 million individuals in the U.S. alone, and for which there is currently no cure. Lewy bodies are also found in nearly half of all Alzheimer's disease patients examined at autopsy.Our lab's current efforts focus on three major themes:
1) The Role of Protein Misfolding in PD and Related Synucleinopathies: Histopathological, genetic, and experimental evidence suggest that the aggregation and accumulation of alpha-synuclein (α-Syn), the primary component of Lewy bodies, underlies the symptoms seen in PD. We previously demonstrated that aggregated forms of α-Syn are transmissible entities that propagate and spread throughout the brain in a manner akin to prion diseases. This exciting discovery represents a significant shift in our understanding of PD etiology and progression. Through the development of novel biophysical, cell-based and animal models, my work seeks to identify factors that a) regulate α-Syn expression and misfolding, b) determine its route of transmission and c) modulate the toxicity of α-Syn pathology.
2) Novel Therapeutics Against Synucleinopathies: Present treatments provide temporary relief to motor impairments but do not alter the neurodegenerative process. In collaboration with UPenn’s Center for Neurodegenerative Disease Research Drug Discovery group, our team has been developing small molecules and biologicals that inhibit the accumulation and transmission of abnormal α-syn species or neutralize their action.
3) Biology of Selective Vulnerability: Synucleinopathies are multisystem disorders that affects only specific cell populations. The reasons for this selective vulnerability is unclear. By characterizing the pathways that govern their development and maintenance, we and others have shown that a susceptible are defined by their connectivity and specific transcription profiles that regulate their function.
This research is conducted by a talented and dedicated team of research specialists, postdoctoral researchers, and students. We are regularly in search of new members.
Selected Publications
Clark RN, Landes RE, Abbas M, Mistretta VG, Jhaveri JR, DeLoatch KA, Franks J, Chen J, Luk KC, Hu X, Leak RK.: Testing an inverse link between limbic alpha-synucleinopathy and myelin markers in mice and humans. NPJ Parkinsons Dis Feb 2026.Luque M, Matic M, Heras-Garvin A, Amo-Aparicio J, Luk KC, Haindl MT, Khalil M, Skouras DB, Dinarello CA, Stefanova N.: Clinically advanced NLRP3 inhibitor modulates microglial transcriptome and alleviates α-synuclein-induced progression of parkinsonism. J Neuroinflammation Jan 2026.
De Schepper S, Konstantellos V, Conway JA, Sokolova D, Zaccagnini L, Cowley MV, Sierksma A, Yudina M, Edmonds M, Gavriouchkina D, Geary B, Wallis A, Celikag M, Baykam Z, Vara-Pérez M, Crowley G, Hager FT, Bijnen M, Posner D, Luk K, Cerovic V, Clatworthy M, Videlock EJ, Jaunmuktane Z, Movahedi K, Greter M, Chain B, Alessi DR, Hong S, Bartels T.: Intestinal macrophages modulate synucleinopathy along the gut-brain axis. Nature Jan 2026.
Lázaro DF, Amen T, Gerhardt E, Song C, Burns R, Kruse N, Santos PI, Milovanovic D, Höglinger G, Mollenhauer B, Luk KC, Lee VM, Outeiro TF.: Synphilin-1 modulates alpha-synuclein assembly, release and uptake. NPJ Parkinsons Dis 11: 326, Nov 2025.
Albert K, Peltonen S, Vanne A, Kälvälä S, Syvänen V, Koistinaho J, Luk KC, Lehtonen Š.: Human microglia reduce alpha-synuclein aggregation and are neuroprotective in adult mouse brain. Brain Behav Immun Nov 2025.
West S, Natalwala A, Singh Dolt K, Lamont DJ, McMillan M, Luk K, Mashimo T, Kunath T.: Glycine-to-aspartic acid mutation at codon 51 in Snca disrupts the synaptic localisation of α-synuclein and enhances its propensity for synucleinopathy. Brain Commun 7: fcaf224, Jun 2025.
Kannarkat GT, Zack R, Skrinak RT, Morley JF, Davila-Rivera R, Arezoumandan S, Dorfman K, Luk K, Wolk DA, Weintraub D, Tropea TF, Lee EB, Xie SX, Chandrasekaran G, Lee VM, Irwin D, Akhtar RS, Chen-Plotkin AS.: Blood α-Synuclein Separates Parkinson's Disease from Dementia with Lewy Bodies. Ann Neurol Jun 2025.
Er S, Parkkinen I, Trepczyk K, Seelbach A, Pasculli MS, De Lorenzo F, Luk K, Jankowska E, Chmielarz P, Domanskyi A, Airavaara M.: GDNF reduces fibril-induced early-stage alpha-synuclein pathology after delivery of 20S proteasome inhibitor lactacystin. Eur J Pharm Sci 208: 107048, May 2025.
Fleming SM, Scott S, Hamad EJ, Herman DE, Holden JG, Yan L, Linning-Duffy K, Kemp CJ, Patterson JR, Miller KM, Kubik M, Kuhn N, Stoll AC, Duffy MF, Steece-Collier K, Cole-Strauss A, Lipton JW, Luk KC, Sortwell CE.: Intrastriatal injection of alpha-synuclein preformed fibrils to rats results in L-DOPA reversible sensorimotor impairments and alterations in non-motor function. Front Neurosci 19: 1556447, Apr 2025.
Han Y, Li J, Xia W, Li Q, Sun Z, Zeng W, Hu Y, Luk KC, Liu C, Xiang S, He Z.: Fibril fuzzy coat is important for α-synuclein pathological transmission activity. Neuron Apr 2025.
© The Trustees of the University of Pennsylvania | Site best viewed in a supported browser. | Site Design: PMACS Web Team.
